Amneal Pharmaceuticals, Inc. reported a net revenue of $722.5 million for the three months ended March 31, 2026, reflecting a 3.9% increase from $695.4 million in the same period last year. The company's gross profit rose significantly to $320.1 million, up 25.1% from $255.9 million in the prior year, driven by a decrease in the cost of goods sold, which fell by 8.4% to $402.4 million. This improvement in profitability was further evidenced by an operating income of $141.8 million, a 41.3% increase compared to $100.3 million in the previous year.
The financial performance was bolstered by growth in the Specialty segment, which saw a 23.1% increase in net revenue to $133.3 million, primarily due to strong sales of products like CREXONT® and BREKIYA®. Conversely, the AvKARE segment experienced a decline in revenue, down 3.7% to $166.0 million, attributed to reduced low-margin distribution sales. The Affordable Medicines segment also contributed positively, with a 2.1% increase in revenue to $423.2 million, driven by sales of women’s health and ADHD medications, despite facing price erosion and a decline in biosimilar sales.
In terms of strategic developments, Amneal announced a definitive agreement to acquire Kashiv BioSciences, LLC for $375 million in cash and stock, with potential contingent payments of up to $350 million based on regulatory milestones. This acquisition is expected to close in the second half of 2026, pending shareholder and regulatory approvals. Additionally, the company incurred acquisition costs of $5.2 million related to this transaction during the reporting period.
Operationally, Amneal's total employee headcount remained stable, and the company continues to focus on expanding its product offerings and market presence. The company reported a significant increase in its cash outflows, with net cash used in operating activities amounting to $26.7 million, primarily due to litigation settlement payments related to the Nationwide Opioids Settlement Agreement. The company anticipates investing approximately $110 million in capital expenditures throughout 2026 to support its operations and growth initiatives.
Looking ahead, Amneal remains cautiously optimistic about its financial outlook, emphasizing the importance of navigating market conditions and regulatory challenges. The company is focused on enhancing its product portfolio and operational efficiencies while managing its debt obligations and capital expenditures effectively.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in developing, manufacturing, marketing, and distributing a broad portfolio of essential medicines. Its business segments include Affordable Medicines (generics, injectables, biosimilars), Specialty branded pharmaceuticals focused on central nervous system and endocrine disorders, and AvKARE, a pharmaceutical distributor serving U.S. government and institutional markets. Amneal leverages complex formulations, vertical integration, and regulatory expertise to deliver cost-effective, high-value pharmaceutical products primarily in the U.S., India, and Ireland.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.